[HTML][HTML] Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized …
O Witzke, M Nitschke, M Bartels, H Wolters… - …, 2018 - journals.lww.com
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized …
O Witzke, M Nitschke, M Bartels, H Wolters, G Wolf… - …, 2018 - europepmc.org
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial.
O Witzke, M Nitschke, M Bartels, H Wolters, G Wolf… - 2018 - cabidigitallibrary.org
Background: The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results after 7 Years of a Randomized …
O Witzke, M Nitschke, M Bartels, H Wolters… - …, 2018 - research.uni-luebeck.de
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized …
O Witzke, M Nitschke, M Bartels, H Wolters, G Wolf… - 2018 - pubmed.ncbi.nlm.nih.gov
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results after 7 Years of a Randomized …
O Witzke, M Nitschke, M Bartels, H Wolters… - …, 2018 - research.uni-luebeck.de
Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …